Neither type of IUD contains estrogen, and neither one is designed to change your estrogen levels. The copper IUD is completely hormone-free, and the hormonal IUD releases a progestin called levonorgestrel that acts primarily inside the uterus. That said, the hormonal IUD is not entirely invisible to the rest of your body, and measurable shifts in estrogen-related markers do show up in research, even if they are subtle compared to methods like the pill or the shot.
How the Two Types of IUDs Differ
There are really two separate conversations here, because the copper IUD and the levonorgestrel IUD work through completely different mechanisms. The copper IUD creates a local inflammatory environment inside the uterus that is toxic to sperm and prevents fertilization. It has no hormones of any kind. The levonorgestrel IUD, on the other hand, slowly releases a synthetic progestin that thins the uterine lining, thickens cervical mucus, and in some users partially suppresses ovulation.1PubMed. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review Because only the hormonal version releases anything into your body, the question of estrogen effects plays out very differently for each type.
What Happens to Estrogen with a Hormonal IUD
The levonorgestrel IUD does not release estrogen, but the progestin it delivers can influence your body’s own estrogen production in a roundabout way. The drug’s primary job is local, keeping the uterine lining thin and cervical mucus thick. But some levonorgestrel does get absorbed into the bloodstream, and at those circulating levels it can partially dampen the hormonal signals that trigger ovulation.
Research looking at ovarian function in women using the levonorgestrel IUD found that while many users still ovulated, the hormonal peaks driving that process were blunted. Preovulatory estradiol levels and the surge of luteinizing hormone that triggers egg release were both lower than in women using a copper IUD or no IUD at all. Even in cycles where ovulation did occur, peak progesterone levels were reduced. Sex hormone-binding globulin, a protein that reflects overall hormonal balance, was also lower in levonorgestrel IUD users compared to copper IUD users.2ScienceDirect. Ovarian function during use of a levonorgestrel-releasing IUD
So the hormonal IUD does nudge estrogen downward to a degree, particularly at its peak moments in the cycle. But this is not the dramatic suppression you see with combined hormonal methods that contain synthetic estrogen themselves, or with injections and implants that deliver higher systemic doses of progestin. For most users, ovarian estrogen production continues at a functional level, which is one reason the hormonal IUD’s side-effect profile tends to be milder than systemic hormonal contraceptives.
Copper IUDs Leave Estrogen Untouched
If your concern is specifically about hormone levels, the copper IUD is about as neutral as a contraceptive method gets. A study comparing copper IUD users to injectable contraceptive users found that serum estrogen, progesterone, and other reproductive hormones stayed within normal ranges in the copper IUD group, with no significant differences between visits.3Middle East Fertility Society Journal. Effect of copper intrauterine device vs. injectable contraceptive on serum hormone levels and cell mitotic activity in endometrium Your ovaries keep cycling the way they normally would. Periods typically continue on their usual schedule, and many users actually notice heavier or crampier periods rather than lighter ones, precisely because the ovary-uterus hormonal loop is uninterrupted.
This distinction matters practically. If you have a condition where maintaining your natural estrogen levels is important, or if you are trying to avoid any interference with your hormonal cycle, the copper IUD is genuinely hormone-neutral in a way that the levonorgestrel version is not.
Mostly Local, Not Whole-Body
One of the selling points of the hormonal IUD is that it delivers progestin directly where it is needed. The concentration of levonorgestrel inside the uterus is far higher than what circulates in the blood. This is why the hormonal IUD can dramatically thin the uterine lining while having relatively modest effects elsewhere.
Early research on progesterone-releasing IUDs showed just how potent this local effect is. Endometrial tissue from women using a progesterone-releasing device had estrogen and progestin receptor levels roughly 80% lower than tissue from women with normal menstrual cycles. That steep drop in receptor activity helps explain why the lining stays thin and bleeding decreases, sometimes to the point of absent periods.4PubMed. Endometrial estrogen and progestin receptors in women bearing a progesterone-releasing intrauterine device
But “mostly local” is not the same as “exclusively local.” The fact that levonorgestrel reaches the bloodstream at all means some tissues beyond the uterus are exposed. The question is whether that exposure is large enough to matter clinically, and that depends on what outcome you are looking at.
Breast Tissue Shows Mixed Signals
One area where researchers have looked for signs of systemic hormonal effects is breast tissue. If levonorgestrel from the IUD were meaningfully altering the hormonal environment, you might expect to see changes in how breast tissue looks on imaging or how it feels.
A contrast-enhanced MRI study found that women with levonorgestrel IUDs showed significantly higher background parenchymal enhancement, a measure of how much breast tissue “lights up” on the scan, compared to the same women when they were not using the device. Nearly half of the women shifted to a higher enhancement category while the IUD was in place.5PubMed Central. Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices The researchers interpreted this as evidence that the hormonal IUD has at least some systemic hormonal effect on breast tissue, since parenchymal enhancement is sensitive to hormonal stimulation.
However, a longer-term mammography study looking at breast density categories over roughly seven and a half years found no association between levonorgestrel IUD use and increased mammographic breast density.6PubMed. Effect of contraceptive hormonal therapy on mammographic breast density: A longitudinal cohort study Breast density on a standard mammogram is a different measurement from contrast-enhanced MRI enhancement, so the two findings are not directly contradictory, but they do paint a nuanced picture. The IUD may be subtly affecting breast tissue physiology without necessarily changing the structural density that screening mammography measures.
A large Danish cross-sectional study adds another piece to this picture. Women using IUDs had modestly higher odds of reporting breast tenderness compared to women not using hormonal contraception, with the association persisting beyond the first year of use.7European Journal of Obstetrics & Gynecology and Reproductive Biology. Hormonal contraception and breast tenderness: A Danish cross-sectional study Breast tenderness is a symptom that can reflect hormonal fluctuation, and the fact that IUD users reported it more often than non-users suggests that the hormonal IUD’s effects are not entirely contained within the uterus.
Effects on Cholesterol and Cardiovascular Markers
Estrogen has well-known effects on lipid metabolism, which is one reason why hormonal contraceptives containing estrogen tend to raise HDL cholesterol and sometimes triglycerides. The levonorgestrel IUD does not contain estrogen, and its progestin component can nudge lipids in a different direction.
In postmenopausal women receiving estrogen therapy through the skin, those who used a levonorgestrel IUD for endometrial protection experienced a transient dip in HDL cholesterol of about 15% at six months, though the effect did not persist. Total cholesterol, triglycerides, and LDL cholesterol did not change significantly in the IUD group.8PubMed. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol
A separate study in women with endometriosis found more dramatic lipid shifts during levonorgestrel IUD use, including reductions in total cholesterol, LDL, and triglycerides, but also a significant drop in HDL.9Contraception. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis That study also saw decreases in inflammatory markers like C-reactive protein. The lipid changes in these patients were more pronounced than what is typically reported in otherwise healthy users, possibly because the baseline levels were higher to begin with.
The practical relevance of these lipid effects is still debated. The shifts tend to be modest in healthy women and sometimes temporary. But they are worth noting because they are another sign that the levonorgestrel IUD is not hormonally silent at the systemic level, even though its estrogen-related effects are much smaller than those of oral contraceptives.
Bone Density and What It Tells Us
Bone health is one of the best indirect ways to assess whether a contraceptive method is lowering estrogen to a concerning degree. Estrogen plays a critical role in maintaining bone mineral density, and methods that suppress it significantly, like certain injectable progestins, have raised concerns about bone loss over time.
The evidence on hormonal IUDs and bone density is reassuring. A rapid review of recent studies found that the large majority of research showed no significant association between hormonal IUD use and changes in bone mineral density. Only one conference abstract reported a negative association, and that was limited to a single skeletal site. Meanwhile, one systematic review actually found that hormonal IUD users had increased bone mineral density compared to other individuals in most of the studies it included.10AJOG Global Reports. Bone mineral density changes during use of progestin-only contraceptives: a rapid review of recent evidence
This bone data is one of the clearest signals that the hormonal IUD is not driving estrogen low enough to cause clinical harm. If estrogen were being meaningfully suppressed over years of use, you would expect to see bone density declining, and the research consistently does not show that. It draws a useful line between the subtle hormonal shifts seen in laboratory measurements and the kind of systemic estrogen suppression that creates real health risks.
The Hormonal IUD in Perimenopause
The interplay between IUDs and estrogen gets especially relevant during perimenopause, when estrogen levels are already fluctuating wildly. Many perimenopausal women still need contraception, since ovulation can occur unpredictably even as cycles become irregular. At the same time, some of these women begin experiencing symptoms like hot flashes and sleep disruption that are driven by declining estrogen.
This is where the hormonal IUD finds a unique role. A woman who is taking estrogen therapy for perimenopausal symptoms still needs something to protect her uterine lining from the growth-promoting effects of that estrogen. Without endometrial protection, estrogen therapy raises the risk of endometrial hyperplasia and cancer. The levonorgestrel IUD can serve as that protective agent while simultaneously providing contraception.11PubMed. Why perimenopausal women should consider to use a levonorgestrel intrauterine system
Studies comparing the levonorgestrel IUD to oral or vaginal progesterone for endometrial protection during estrogen therapy found it equally effective at preventing hyperplasia.12PubMed Central. Benefits of Levonorgestrel Intrauterine Device Use vs. Oral or Transdermal Progesterone for Postmenopausal Women Using Estrogen Containing Hormone Therapy The advantage of the IUD route is convenience and adherence. You do not need to remember a daily pill or use vaginal inserts; the progestin delivery is continuous and automatic. For women who are simultaneously managing irregular bleeding, which is common in perimenopause, the IUD’s lining-thinning effect can also help control heavy periods while their estrogen therapy addresses vasomotor symptoms.
To be clear, in this scenario the IUD is not the source of estrogen. It is working alongside separately prescribed estrogen, delivering the progestin component locally so that the woman can take estrogen without the risks of an unprotected uterine lining. The IUD itself is not raising or replacing estrogen in any way.
PCOS and the Hormonal IUD
Polycystic ovary syndrome adds yet another layer to this question. Women with PCOS often have higher-than-normal levels of androgens and may have irregular estrogen patterns due to inconsistent or absent ovulation. Combined oral contraceptives are frequently prescribed to manage PCOS symptoms because they supply estrogen and regulate cycles, but some women cannot or prefer not to take estrogen-containing methods.
The levonorgestrel IUD offers contraception and endometrial protection for women with PCOS who are at risk of endometrial buildup due to chronic anovulation. An observational study in non-obese women with PCOS found that six months of levonorgestrel IUD use improved markers of excess androgens and lowered LDL and total cholesterol. However, the same study noted increases in waist circumference and fasting blood sugar.13Endocrinology and Metabolism. An Update on Contraception in Polycystic Ovary Syndrome
The IUD does not address the estrogen-related aspects of PCOS management the way combined pills do. It will not regulate cycles into a predictable monthly pattern, and it will not provide the estrogen that helps suppress ovarian androgen production. For women whose primary goal is cycle regularity and androgen control, the hormonal IUD is an incomplete solution. For women whose primary concern is contraception and endometrial safety with minimal systemic hormonal exposure, it may be a good fit, but monitoring metabolic markers is reasonable given the observed changes in glucose and waist circumference.
When the “Hormone-Free” Label Gets Confusing
Marketing around IUDs sometimes creates confusion. The copper IUD is genuinely hormone-free. The levonorgestrel IUD is sometimes described in casual conversation as “not really hormonal” because it acts locally, but this framing understates its systemic reach. Calling it “low-hormone” or “locally acting” is more accurate than “hormone-free,” and the research on ovarian function, breast tissue, lipid markers, and breast tenderness all confirm that the body notices the levonorgestrel even though the dose reaching the bloodstream is small.
At the same time, framing the hormonal IUD as equivalent to the pill or the patch overstates things in the opposite direction. Combined hormonal methods deliver synthetic estrogen plus progestin systemically and have a different risk profile, including effects on blood clotting, blood pressure, and migraine. The levonorgestrel IUD avoids all estrogen-related risks because it simply does not contain or deliver estrogen. The subtle changes it produces in your body’s own estrogen are measurable in studies but do not appear to carry the same clinical weight.
If you are choosing a contraceptive method and estrogen is a specific concern, whether because of migraine with aura, a history of blood clots, or personal preference, the distinction between the two IUD types matters. The copper IUD leaves your hormonal system entirely alone. The levonorgestrel IUD leaves your estrogen mostly alone while delivering progestin in a way that has small but real systemic effects. Neither one adds estrogen to your body, and neither one suppresses estrogen to a degree that appears to threaten bone health or other estrogen-dependent functions over the long term.